Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Noel Marie-France Thomsen"'
Autor:
Noel Marie-France Thomsen, Simone Bonazzi, Stephanie M. McTighe, Guiqing Liang, Danuta Lubicka, Sarah Salas, Jill Nunez, Franco Lombardo, Rajeshri Ganesh Karki, Audrey Gray, Stefan Peukert, Doug Burdette, Jean-Cosme Dodart, Leon Murphy, Grazia Piizzi, Carleton Goold, Labbe-Giguere Nancy, Erin P. Keaney, Jonathan D. Biag, Christine D. Wilson, Aakruti Gorde, Lawrence G. Hamann, Yingchuan Sun, Lin Deng, Hasnain A. Malik, Daniel Curtis, Shanming Liu
Publikováno v:
Journal of medicinal chemistry. 63(3)
Recent clinical evaluation of everolimus for seizure reduction in patients with tuberous sclerosis complex (TSC), a disease with overactivated mechanistic target of rapamycin (mTOR) signaling, has demonstrated the therapeutic value of mTOR inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3487e6cec3e46116122d50f027546e53
https://pubmed.ncbi.nlm.nih.gov/31955578
https://pubmed.ncbi.nlm.nih.gov/31955578
Autor:
Yuji Mishina, Jianling Wang, Choi-Lai Tiong-Yip, He Guo, Noel Marie-France Thomsen, Jill Nunez, Franco Lombardo, Clayton Springer, Jason Baird, L. Alex Gaither, John D. Norris, Sunkyu Kim, Brant Firestone, Stefan Peukert, Kaitlin J. Macchi, Donald P. McDonnell, Tinya Abrams, Chunrong Wang, Bing Yu, Lawrence G. Hamann, Yingchuan Sun, Burks Heather Elizabeth, Christina A. Kirby, George Scott Tria
Publikováno v:
Journal of Medicinal Chemistry. 61:2837-2864
In breast cancer, estrogen receptor alpha (ERα) positive cancer accounts for approximately 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation. Treatment of ERα positive breast cancer has long relied on endocri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::281b788e18778a84f111fefb917205c1
https://doi.org/10.1021/acs.jmedchem.7b01682
https://doi.org/10.1021/acs.jmedchem.7b01682
Autor:
Burks Heather Elizabeth, Noel Marie-France Thomsen, Alexander Fekete, Alice Loo, Christina A. Kirby, Lawrence G. Hamann, Yingchuan Sun, Chunrong Wang, Jianling Wang, Chitra Saran, Danuta Lubicka, Donald P. McDonnell, Yuji Mishina, Franco Lombardo, Jason Baird, Tinya Abrams, Kaitlin J. Macchi, Stefan Peukert, Jill Nunez, John D. Norris, Sunkyu Kim
Publikováno v:
Journal of medicinal chemistry. 60(7)
Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo. We outline the discovery and chemical opti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd2485b0e5060d74e1c48169d18047b1
https://pubmed.ncbi.nlm.nih.gov/28296398
https://pubmed.ncbi.nlm.nih.gov/28296398